Emerging HIV Therapies and Potential Clinical Uses

Volume 8, Issue 4

Emerging HIV Therapies and Potential Clinical Uses

In this issue:

Patients with HIV that cannot be treated with currently available therapies because of multiple resistance mutations. ART with cumbersome dosing schedules that require patient adherence to maintain full effectiveness. Approved PrEP treatments with outstanding success rates that go unused. Potential impact of therapies that are on the horizon.

Can new and emerging HIV treatment options help clinicians overcome barriers to improving their patients’ health? That’s what we’ll be discussing with infectious disease specialists Drs. Meredith Clement and Lauren Richey from the Louisiana State University Health Sciences Center in New Orleans, in this issue of eHIV Review.

Learning objectives:

Describe the potential uses of emerging therapies (including broadly neutralizing monoclonal antibodies and lenacapavir) for the treatment of HIV.
Describe the potential uses of emerging medications (including islatravir and broadly neutralizing antibodies) in the prevention of HIV.

Authors:

Meredith E. Clement, MD

Assistant Professor, Section of Infectious Disease
Louisiana State University Health Sciences Center, New Orleans

Lauren Richey, MD, MPH, FIDSA

Associate Professor, Section of Infectious Disease
Louisiana State University Health Sciences Center, New Orleans

Guest Faculty Disclosures

Dr. Clement has disclosed membership on advisory committees or review panels, board membership, etc for ViiV Healthcare and Roche. She has received royalties or patent beneficiary from UpToDate, as well as grant or research support from ViiV Healthcare and Gilead Sciences, Inc.

Dr. Richey has indicated that she has no financial interests in or relationships with a commercial entity.

Unlabeled/Unapproved Uses

Dr. Clement and Dr. Richey have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Program Directors:

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Guest Faculty Disclosures:

Dr. Richey has indicated that she has no financial interests in or relationships with a commercial entity.

Unlabeled/Unapproved Uses:

Dr. Clement and Dr. Richey have indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: April 27, 2023
Expiration date: April 26, 2025

Start Issue